Constantly condensing the truth

In May 2024, he joined Shanghai Lishan Biopharmaceutical Co., Ltd. as the chief consultant of the Advisory Committee;

Appointed as Scientific Advisory Board in October 2024 chairman

Doctor of Pathology, McGill University, Canada, postdoctoral fellow, Harvard Medical School, USA. Since 1994, he has served as a new drug reviewer for the US FDA for seven years. After leaving FDA at the end of 2000, he successively served as Director of Registration Department of United Health Insurance Company in the United States and Senior Director of Clinical and Registration Department of Hutchison Whampoa Medicine in Hong Kong. Since then, he has served as CEO and chief Pharmaceutical development Consultant at Humphrey Pharmaceutical Consulting Co., LTD., leading a new drug development team from different countries, different cultural backgrounds and different specialties to successfully complete the development and application of more than 100 new drugs. He is currently a visiting professor of Union Medical College, President of FDA Expert Society, president of Tongxieyi Talent Club, and chair-designate of International Regulatory Committee of Pharmaceutical Promotion Association.